Alzheimer's disease (AD) is one of the main causes of dementia worldwide, whereby neuronal death or malfunction leads to cognitive impairment in the elderly population. AD is highly prevalent, with increased projections over the next few decades. Yet current diagnostic methods for AD occur only after the presentation of clinical symptoms. Evidence in the literature points to potential mechanisms of AD induction beginning before clinical symptoms start to present, such as the formation of amyloid beta (A
β) extracellular plaques and neurofibrillary tangles (NFTs). Biomarkers of AD, including A β40, A β42, and tau protein, amongst others, show promise for early AD diagnosis. Additional progress is made in the application of biosensing modalities to measure and detect significant changes in these AD biomarkers within patient samples, such as cerebral spinal fluid (CSF) and blood, serum, or plasma. Herein, a comprehensive review of the emerging nano‐biomaterial approaches to develop biosensors for AD biomarkers’ detection is provided. Advances, challenges, and potential of electrochemical, optical, and colorimetric biosensors, focusing on nanoparticle‐based (metallic, magnetic, quantum dots) and nanostructure‐based biomaterials are discussed. Finally, the criteria for incorporating these emerging nano‐biomaterials in clinical settings are presented and assessed, as they hold great potential for enhancing early‐onset AD diagnostics.